PlasmaGen Biosciences has successfully raised INR 225 crore (approximately $27 million) in equity funding. The funding round, led by UK-based investment management firm Artian Investments, along with contributions from high-net-worth individuals (HNIs) including investor Ashish Rameshchandra Kacholia, solidifies PlasmaGen’s position as a key player in the field.
Investor Confidence and Diverse Participation
The funding initiative saw the active participation of Artian Investments and Ashish Rameshchandra Kacholia, known for his strategic investments in companies and proficiency in navigating public markets. Notably, early backers Eight Roads Ventures and existing investor F-Prime Capital also reaffirmed their confidence in PlasmaGen’s vision.
A Boost for Plasma Products and Global Presence
PlasmaGen Biosciences, headquartered in Bengaluru, is dedicated to producing blood plasma-derived pharmaceutical products. The company’s portfolio includes critical drugs such as albumin and hepatitis B immunoglobulin, distributed under its own brand name to private hospitals and state governments not only in India but also in other emerging markets.
The substantial funding injection is earmarked to accelerate the growth of plasma products and facilitate the company’s international expansion. With an eye on diversifying its product offerings and addressing working capital needs, PlasmaGen is poised to make significant strides in the global biopharmaceutical landscape.
Cumulative Success and Future Vision
Established in 2010, PlasmaGen Biosciences has successfully raised a cumulative total of INR 400 crore, underscoring its ability to attract sustained investor interest over the years. Founder and Managing Director, Vinod Nahar, expressed gratitude to the investors, emphasizing, “This latest funding strengthens our position in our mission to be a trusted and leading Indian biopharmaceutical company.”
State-of-the-Art Manufacturing Facility and National Presence
Earlier this year, PlasmaGen achieved a significant milestone with the inauguration of a cutting-edge manufacturing facility for blood plasma-derived protein therapeutics in Kolar. With an initial capacity to process 500,000 liters of plasma annually, this facility reflects PlasmaGen’s commitment to advancing biopharmaceutical capabilities.
The company has successfully established a national presence, reaching over 70 cities in India and collaborating with more than 5,000 physicians and hospitals. This extensive network positions PlasmaGen as a reliable provider of critical pharmaceuticals across diverse geographical areas.
Strategic Targets and Industry Contribution
PlasmaGen Biosciences has set ambitious targets, aiming for a turnover of nearly INR 640 crore within the next five years. This strategic vision aligns with the company’s commitment to robust product growth, emphasizing its dedication to advancing the field of biopharmaceuticals.
The successful completion of this equity funding round not only validates investor confidence in PlasmaGen’s business model but also positions the company strongly to contribute significantly to the healthcare landscape. As the biopharmaceutical sector continues to evolve, PlasmaGen Biosciences stands poised to play a pivotal role in shaping the future of accessible and life-saving medical solutions.
